Report cover image

Global Granulocyte Macrophage Colony Stimulating Factor Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 193 Pages
SKU # APRC20556451

Description

Summary

According to APO Research, the global Granulocyte Macrophage Colony Stimulating Factor market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Granulocyte Macrophage Colony Stimulating Factor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Granulocyte Macrophage Colony Stimulating Factor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Granulocyte Macrophage Colony Stimulating Factor market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Granulocyte Macrophage Colony Stimulating Factor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Granulocyte Macrophage Colony Stimulating Factor market include Takeda Pharmaceutical Co Ltd, GlaxoSmithKline Plc, Amgen Inc, Sillajen Biotherapeutics, Morphotek Inc, Mologen AG, Humanigen Inc, Cold Genesys Inc and BriaCell Therapeutics Corp, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Granulocyte Macrophage Colony Stimulating Factor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Granulocyte Macrophage Colony Stimulating Factor, also provides the sales of main regions and countries. Of the upcoming market potential for Granulocyte Macrophage Colony Stimulating Factor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Granulocyte Macrophage Colony Stimulating Factor sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Granulocyte Macrophage Colony Stimulating Factor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Granulocyte Macrophage Colony Stimulating Factor sales, projected growth trends, production technology, application and end-user industry.

Granulocyte Macrophage Colony Stimulating Factor Segment by Company

Takeda Pharmaceutical Co Ltd
GlaxoSmithKline Plc
Amgen Inc
Sillajen Biotherapeutics
Morphotek Inc
Mologen AG
Humanigen Inc
Cold Genesys Inc
BriaCell Therapeutics Corp
Aduro BioTech Inc
Granulocyte Macrophage Colony Stimulating Factor Segment by Type

CG-0070
Lenzilumab
Gimsilumab
MGN-1601
GSK-3196165
Others
Granulocyte Macrophage Colony Stimulating Factor Segment by Application

Solid Tumor
Kidney Cancer
Lymphoma
Lung Disease
Others
Granulocyte Macrophage Colony Stimulating Factor Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Granulocyte Macrophage Colony Stimulating Factor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Granulocyte Macrophage Colony Stimulating Factor market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Granulocyte Macrophage Colony Stimulating Factor significant trends, drivers, influence factors in global and regions.
6. To analyze Granulocyte Macrophage Colony Stimulating Factor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte Macrophage Colony Stimulating Factor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Granulocyte Macrophage Colony Stimulating Factor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte Macrophage Colony Stimulating Factor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Granulocyte Macrophage Colony Stimulating Factor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Granulocyte Macrophage Colony Stimulating Factor industry.
Chapter 3: Detailed analysis of Granulocyte Macrophage Colony Stimulating Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Granulocyte Macrophage Colony Stimulating Factor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Granulocyte Macrophage Colony Stimulating Factor in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value (2020-2031)
1.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume (2020-2031)
1.2.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Granulocyte Macrophage Colony Stimulating Factor Market Dynamics
2.1 Granulocyte Macrophage Colony Stimulating Factor Industry Trends
2.2 Granulocyte Macrophage Colony Stimulating Factor Industry Drivers
2.3 Granulocyte Macrophage Colony Stimulating Factor Industry Opportunities and Challenges
2.4 Granulocyte Macrophage Colony Stimulating Factor Industry Restraints
3 Granulocyte Macrophage Colony Stimulating Factor Market by Company
3.1 Global Granulocyte Macrophage Colony Stimulating Factor Company Revenue Ranking in 2024
3.2 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Company (2020-2025)
3.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Company (2020-2025)
3.4 Global Granulocyte Macrophage Colony Stimulating Factor Average Price by Company (2020-2025)
3.5 Global Granulocyte Macrophage Colony Stimulating Factor Company Ranking (2023-2025)
3.6 Global Granulocyte Macrophage Colony Stimulating Factor Company Manufacturing Base and Headquarters
3.7 Global Granulocyte Macrophage Colony Stimulating Factor Company Product Type and Application
3.8 Global Granulocyte Macrophage Colony Stimulating Factor Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Granulocyte Macrophage Colony Stimulating Factor Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Granulocyte Macrophage Colony Stimulating Factor Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Granulocyte Macrophage Colony Stimulating Factor Market by Type
4.1 Granulocyte Macrophage Colony Stimulating Factor Type Introduction
4.1.1 CG-0070
4.1.2 Lenzilumab
4.1.3 Gimsilumab
4.1.4 MGN-1601
4.1.5 GSK-3196165
4.1.6 Others
4.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Type
4.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Type (2020-2031)
4.2.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share by Type (2020-2031)
4.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Type
4.3.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Type (2020-2031)
4.3.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type (2020-2031)
5 Granulocyte Macrophage Colony Stimulating Factor Market by Application
5.1 Granulocyte Macrophage Colony Stimulating Factor Application Introduction
5.1.1 Solid Tumor
5.1.2 Kidney Cancer
5.1.3 Lymphoma
5.1.4 Lung Disease
5.1.5 Others
5.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Application
5.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Application (2020-2031)
5.2.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share by Application (2020-2031)
5.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Application
5.3.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Application (2020-2031)
5.3.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application (2020-2031)
6 Granulocyte Macrophage Colony Stimulating Factor Regional Sales and Value Analysis
6.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region (2020-2031)
6.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region: 2020-2025
6.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region (2026-2031)
6.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Region (2020-2031)
6.4.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Region: 2020-2025
6.4.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Region (2026-2031)
6.5 Global Granulocyte Macrophage Colony Stimulating Factor Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Granulocyte Macrophage Colony Stimulating Factor Sales Value (2020-2031)
6.6.2 North America Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Granulocyte Macrophage Colony Stimulating Factor Sales Value (2020-2031)
6.7.2 Europe Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Sales Value (2020-2031)
6.8.2 Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Granulocyte Macrophage Colony Stimulating Factor Sales Value (2020-2031)
6.9.2 South America Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Granulocyte Macrophage Colony Stimulating Factor Sales Value (2020-2031)
6.10.2 Middle East & Africa Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country, 2024 VS 2031
7 Granulocyte Macrophage Colony Stimulating Factor Country-level Sales and Value Analysis
7.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2020-2031)
7.3.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2020-2025)
7.3.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2026-2031)
7.4 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Country (2020-2031)
7.4.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Country (2020-2025)
7.4.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.5.2 USA Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.6.2 Canada Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.8.2 Germany Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.9.2 France Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.9.3 France Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.11.2 Italy Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.12.2 Spain Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.13.2 Russia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.16.2 China Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.16.3 China Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.17.2 Japan Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.19.2 India Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.19.3 India Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.20.2 Australia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.24.2 Chile Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.26.2 Peru Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.28.2 Israel Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.29.2 UAE Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.31.2 Iran Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Takeda Pharmaceutical Co Ltd
8.1.1 Takeda Pharmaceutical Co Ltd Comapny Information
8.1.2 Takeda Pharmaceutical Co Ltd Business Overview
8.1.3 Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2020-2025)
8.1.4 Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
8.1.5 Takeda Pharmaceutical Co Ltd Recent Developments
8.2 GlaxoSmithKline Plc
8.2.1 GlaxoSmithKline Plc Comapny Information
8.2.2 GlaxoSmithKline Plc Business Overview
8.2.3 GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2020-2025)
8.2.4 GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
8.2.5 GlaxoSmithKline Plc Recent Developments
8.3 Amgen Inc
8.3.1 Amgen Inc Comapny Information
8.3.2 Amgen Inc Business Overview
8.3.3 Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2020-2025)
8.3.4 Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
8.3.5 Amgen Inc Recent Developments
8.4 Sillajen Biotherapeutics
8.4.1 Sillajen Biotherapeutics Comapny Information
8.4.2 Sillajen Biotherapeutics Business Overview
8.4.3 Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2020-2025)
8.4.4 Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
8.4.5 Sillajen Biotherapeutics Recent Developments
8.5 Morphotek Inc
8.5.1 Morphotek Inc Comapny Information
8.5.2 Morphotek Inc Business Overview
8.5.3 Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2020-2025)
8.5.4 Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
8.5.5 Morphotek Inc Recent Developments
8.6 Mologen AG
8.6.1 Mologen AG Comapny Information
8.6.2 Mologen AG Business Overview
8.6.3 Mologen AG Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2020-2025)
8.6.4 Mologen AG Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
8.6.5 Mologen AG Recent Developments
8.7 Humanigen Inc
8.7.1 Humanigen Inc Comapny Information
8.7.2 Humanigen Inc Business Overview
8.7.3 Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2020-2025)
8.7.4 Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
8.7.5 Humanigen Inc Recent Developments
8.8 Cold Genesys Inc
8.8.1 Cold Genesys Inc Comapny Information
8.8.2 Cold Genesys Inc Business Overview
8.8.3 Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2020-2025)
8.8.4 Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
8.8.5 Cold Genesys Inc Recent Developments
8.9 BriaCell Therapeutics Corp
8.9.1 BriaCell Therapeutics Corp Comapny Information
8.9.2 BriaCell Therapeutics Corp Business Overview
8.9.3 BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2020-2025)
8.9.4 BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
8.9.5 BriaCell Therapeutics Corp Recent Developments
8.10 Aduro BioTech Inc
8.10.1 Aduro BioTech Inc Comapny Information
8.10.2 Aduro BioTech Inc Business Overview
8.10.3 Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2020-2025)
8.10.4 Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
8.10.5 Aduro BioTech Inc Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Granulocyte Macrophage Colony Stimulating Factor Value Chain Analysis
9.1.1 Granulocyte Macrophage Colony Stimulating Factor Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Granulocyte Macrophage Colony Stimulating Factor Sales Mode & Process
9.2 Granulocyte Macrophage Colony Stimulating Factor Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Granulocyte Macrophage Colony Stimulating Factor Distributors
9.2.3 Granulocyte Macrophage Colony Stimulating Factor Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.